CA3227360A1 - Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders - Google Patents
Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders Download PDFInfo
- Publication number
- CA3227360A1 CA3227360A1 CA3227360A CA3227360A CA3227360A1 CA 3227360 A1 CA3227360 A1 CA 3227360A1 CA 3227360 A CA3227360 A CA 3227360A CA 3227360 A CA3227360 A CA 3227360A CA 3227360 A1 CA3227360 A1 CA 3227360A1
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- methylone
- disorders
- anxiety
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230237P | 2021-08-06 | 2021-08-06 | |
| US63/230,237 | 2021-08-06 | ||
| US202163240113P | 2021-09-02 | 2021-09-02 | |
| US63/240,113 | 2021-09-02 | ||
| US202163255706P | 2021-10-14 | 2021-10-14 | |
| US63/255,706 | 2021-10-14 | ||
| US202263325757P | 2022-03-31 | 2022-03-31 | |
| US63/325,757 | 2022-03-31 | ||
| US202263328343P | 2022-04-07 | 2022-04-07 | |
| US63/328,343 | 2022-04-07 | ||
| PCT/US2022/074369 WO2023015154A1 (en) | 2021-08-06 | 2022-08-01 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3227360A1 true CA3227360A1 (en) | 2023-02-09 |
Family
ID=85156410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3227360A Pending CA3227360A1 (en) | 2021-08-06 | 2022-08-01 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US11707446B2 (https=) |
| EP (1) | EP4380588A4 (https=) |
| JP (1) | JP2024530007A (https=) |
| KR (1) | KR20240072133A (https=) |
| AU (1) | AU2022325135A1 (https=) |
| CA (1) | CA3227360A1 (https=) |
| IL (1) | IL310334A (https=) |
| MX (1) | MX2024001654A (https=) |
| TW (1) | TW202327571A (https=) |
| WO (1) | WO2023015154A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024254190A2 (en) * | 2023-06-06 | 2024-12-12 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US12295937B2 (en) | 2021-08-06 | 2025-05-13 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US12343326B2 (en) | 2021-08-06 | 2025-07-01 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| MX2024001654A (es) | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| KR20240165982A (ko) * | 2022-03-31 | 2024-11-25 | 트랜센드 테라퓨틱스 인코퍼레이티드 | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039133A1 (en) * | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
| US8575194B1 (en) | 2004-08-31 | 2013-11-05 | Jack William Schultz | Treatment methods of cognitive, emotional and mental ailments and disorders |
| US20120108510A1 (en) | 2010-05-20 | 2012-05-03 | Emory University | Methods of improving behavioral therapies |
| EP2931291B1 (en) | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| WO2017151980A1 (en) | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| WO2021257500A1 (en) | 2020-06-17 | 2021-12-23 | Lobe Sciences Ltd. | Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder |
| JP2024512796A (ja) * | 2021-04-01 | 2024-03-19 | テラン バイオサイエンシーズ インク． | サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物 |
| MX2024001654A (es) | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| EP4426685A4 (en) * | 2021-11-05 | 2026-01-07 | Terran Biosciences Inc | Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use |
-
2022
- 2022-08-01 MX MX2024001654A patent/MX2024001654A/es unknown
- 2022-08-01 IL IL310334A patent/IL310334A/en unknown
- 2022-08-01 JP JP2024506546A patent/JP2024530007A/ja active Pending
- 2022-08-01 AU AU2022325135A patent/AU2022325135A1/en active Pending
- 2022-08-01 CA CA3227360A patent/CA3227360A1/en active Pending
- 2022-08-01 WO PCT/US2022/074369 patent/WO2023015154A1/en not_active Ceased
- 2022-08-01 KR KR1020247007349A patent/KR20240072133A/ko active Pending
- 2022-08-01 EP EP22854040.7A patent/EP4380588A4/en active Pending
- 2022-08-05 TW TW111129588A patent/TW202327571A/zh unknown
- 2022-08-15 US US17/887,962 patent/US11707446B2/en active Active
-
2023
- 2023-06-28 US US18/215,547 patent/US12059402B2/en active Active
- 2023-11-02 US US18/386,337 patent/US11969407B2/en active Active
-
2024
- 2024-05-09 US US18/659,413 patent/US12233046B2/en active Active
-
2025
- 2025-01-16 US US19/024,616 patent/US20250255846A1/en active Pending
- 2025-12-04 US US19/409,215 patent/US20260083699A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240058301A1 (en) | 2024-02-22 |
| WO2023015154A1 (en) | 2023-02-09 |
| US20240293357A1 (en) | 2024-09-05 |
| EP4380588A1 (en) | 2024-06-12 |
| US11969407B2 (en) | 2024-04-30 |
| US20230054211A1 (en) | 2023-02-23 |
| TW202327571A (zh) | 2023-07-16 |
| US12059402B2 (en) | 2024-08-13 |
| US20250255846A1 (en) | 2025-08-14 |
| KR20240072133A (ko) | 2024-05-23 |
| US11707446B2 (en) | 2023-07-25 |
| JP2024530007A (ja) | 2024-08-14 |
| US12233046B2 (en) | 2025-02-25 |
| IL310334A (en) | 2024-03-01 |
| EP4380588A4 (en) | 2025-10-08 |
| US20260083699A1 (en) | 2026-03-26 |
| MX2024001654A (es) | 2024-06-28 |
| US20230338333A1 (en) | 2023-10-26 |
| AU2022325135A1 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11969407B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| WO2019213551A1 (en) | Methods of treating substance abuse | |
| JPH01250315A (ja) | 脳機能改善剤 | |
| EP2968220B1 (en) | Methods and compositions for improving cognitive function | |
| CA2816595A1 (en) | Combination therapy for the treatment of depression and other non-infectious diseases | |
| EP4499066A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US20250221957A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| WO2004045718A2 (en) | Treatment of cognitive dysfunctions' | |
| US12343326B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US12295937B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US20250332139A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| HK40112015A (zh) | 精神作用药物及其用於治疗精神和神经病状和病症的用途 | |
| CN118434416A (zh) | 精神作用药物及其用于治疗精神和神经病状和病症的用途 | |
| EP4724433A2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| WO2024254190A2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| HK40120411A (zh) | 精神作用药物及其用於治疗精神和神经病状和病症的用途 | |
| JP2024508372A (ja) | 注意欠陥／多動性障害の治療又は予防に使用するための化合物 | |
| KR20260053276A (ko) | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 | |
| Erkizia-Santamaría et al. | Progress in Neuropsychopharmacology & Biological Psychiatry | |
| HK1220364B (en) | Methods and compositions for improving cognitive function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250709 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250709 |